Under his leadership, Galapagos has developed a large pipeline of novel mechanism of action drugs; Jyseleca was approved for rheumatoid arthritis in 2020 in the EU and Japan. He has supervised multiple successful proofs-of-concept patient studies, including filgotinib and ziritaxestat.
Prior to his tenure at Galapagos, Piet Wigerinck was Vice President, Drug Discovery, Early Development and CM&C at Tibotec-Virco Comm. VA (a subsidiary of Johnson & Johnson Services, Inc.). Under his leadership at Tibotec Prezista™, Olysio™, and Rekambys™ were selected, moved forward into clinical trials and later approved. Piet Wigerinck has over 30 years of R&D experience in the pharmaceutical industry and biotechnology. He holds a Ph.D. from the K.U. Leuven and is inventor on more than 25 patent applications. In May 2018, he was elected an independent board member of French pharmaceutical company Ipsen SA.